{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:05:52Z","timestamp":1794254752632,"version":"4.9.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Health Science and Technology Project of Zhejiang Provincial Health Commission","award":["2023KY389"],"award-info":[{"award-number":["2023KY389"]}]},{"name":"Medical Health Science and Technology Project of Zhejiang Provincial Health Commission","award":["2023KY389"],"award-info":[{"award-number":["2023KY389"]}]},{"name":"Medical Health Science and Technology Project of Zhejiang Provincial Health Commission","award":["2023KY389"],"award-info":[{"award-number":["2023KY389"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01624-z","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T13:01:11Z","timestamp":1743685271000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["N6-methyladenosine-mediated upregulation of H19 promotes resistance to bortezomib by modulating the miR-184\/CARM1 axis in multiple myeloma"],"prefix":"10.1007","volume":"25","author":[{"given":"Gang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"issue":"5","key":"1624_CR1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"1624_CR2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","volume":"37 Suppl 1","author":"SV Rajkumar","year":"2019","unstructured":"Rajkumar SV. Multiple myeloma: every year a new standard? Hematol Oncol. 2019;37 Suppl 1(Suppl 1):62\u20135.","journal-title":"Hematol Oncol"},{"issue":"5","key":"1624_CR3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ejh.13840","volume":"109","author":"CY Soekojo","year":"2022","unstructured":"Soekojo CY, Chng WJ. Treatment horizon in multiple myeloma. Eur J Haematol. 2022;109(5):425\u201340.","journal-title":"Eur J Haematol"},{"issue":"4","key":"1624_CR4","first-page":"CD010816","volume":"4","author":"K Scott","year":"2016","unstructured":"Scott K, et al. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 2016;4(4):CD010816.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1624_CR5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","volume":"8","author":"RC Kane","year":"2003","unstructured":"Kane RC, et al. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8(6):508\u201313.","journal-title":"Oncologist"},{"issue":"9","key":"1624_CR6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14740338.2018.1513487","volume":"17","author":"G Cengiz Seval","year":"2018","unstructured":"Cengiz Seval G, Beksac M. The safety of bortezomib for the treatment of multiple myeloma. Expert Opin Drug Saf. 2018;17(9):953\u201362.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1624_CR7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000087894","volume":"114","author":"M Politou","year":"2005","unstructured":"Politou M, et al. Anti-angiogenic effect of bortezomib in patients with multiple myeloma. Acta Haematol. 2005;114(3):170\u20133.","journal-title":"Acta Haematol"},{"issue":"3","key":"1624_CR8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrm.2017.104","volume":"19","author":"JD Ransohoff","year":"2018","unstructured":"Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19(3):143\u201357.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"16","key":"1624_CR9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2217\/bmm-2022-0349","volume":"16","author":"S Leng","year":"2022","unstructured":"Leng S, et al. Role of ncRNA in multiple myeloma. Biomark Med. 2022;16(16):1181\u201391.","journal-title":"Biomark Med"},{"issue":"1","key":"1624_CR10","doi-asserted-by":"crossref","first-page":"6557","DOI":"10.1038\/s41598-018-24701-8","volume":"8","author":"D Ronchetti","year":"2018","unstructured":"Ronchetti D, et al. A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma. Sci Rep. 2018;8(1):6557.","journal-title":"Sci Rep"},{"key":"1624_CR11","doi-asserted-by":"crossref","first-page":"e1812","DOI":"10.1002\/wrna.1812","volume":"89","author":"H Zhou","year":"2023","unstructured":"Zhou H, et al. Noncoding RNA mutations in cancer. Wiley Interdiscip Rev RNA. 2023;89:e1812.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"1","key":"1624_CR12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41392-021-00779-x","volume":"6","author":"C Li","year":"2021","unstructured":"Li C, et al. Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. Signal Transduct Target Ther. 2021;6(1):383.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"1624_CR13","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.bbamcr.2014.03.023","volume":"1843","author":"IJ Matouk","year":"2014","unstructured":"Matouk IJ, et al. Oncofetal H19 RNA promotes tumor metastasis. Biochim Biophys Acta. 2014;1843(7):1414\u201326.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"1624_CR14","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1159\/000480028","volume":"42","author":"J Yan","year":"2017","unstructured":"Yan J, et al. Long Noncoding RNA H19\/miR-675 axis promotes gastric cancer via FADD\/caspase 8\/caspase 3 signaling pathway. Cell Physiol Biochem. 2017;42(6):2364\u201376.","journal-title":"Cell Physiol Biochem"},{"issue":"4","key":"1624_CR15","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1002\/jcb.26521","volume":"119","author":"A Zhang","year":"2018","unstructured":"Zhang A, et al. Long non-coding RNA H19 suppresses retinoblastoma progression via counteracting miR-17-92 cluster. J Cell Biochem. 2018;119(4):3497\u2013509.","journal-title":"J Cell Biochem"},{"issue":"16","key":"1624_CR16","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1111\/febs.12902","volume":"281","author":"M Zhu","year":"2014","unstructured":"Zhu M, et al. lncRNA H19\/miR-675 axis represses prostate cancer metastasis by targeting TGFBI. FEBS J. 2014;281(16):3766\u201375.","journal-title":"FEBS J"},{"issue":"4","key":"1624_CR17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.molcel.2019.04.025","volume":"74","author":"H Shi","year":"2019","unstructured":"Shi H, Wei J, He C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol Cell. 2019;74(4):640\u201350.","journal-title":"Mol Cell"},{"issue":"3","key":"1624_CR18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","volume":"37","author":"H Huang","year":"2020","unstructured":"Huang H, Weng H, Chen J. m(6)A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;37(3):270\u201388.","journal-title":"Cancer Cell"},{"issue":"1","key":"1624_CR19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12943-020-01207-4","volume":"19","author":"Y Chen","year":"2020","unstructured":"Chen Y, et al. Interaction between N(6)-methyladenosine (m(6)A) modification and noncoding RNAs in cancer. Mol Cancer. 2020;19(1):94.","journal-title":"Mol Cancer"},{"issue":"3","key":"1624_CR20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41418-021-00879-9","volume":"29","author":"HT Liu","year":"2022","unstructured":"Liu HT, et al. lncRNA THAP7-AS1, transcriptionally activated by SP1 and post-transcriptionally stabilized by METTL3-mediated m6A modification, exerts oncogenic properties by improving CUL4B entry into the nucleus. Cell Death Differ. 2022;29(3):627\u201341.","journal-title":"Cell Death Differ"},{"issue":"7","key":"1624_CR21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41419-022-05050-x","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, et al. m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression. Cell Death Dis. 2022;13(7):657.","journal-title":"Cell Death Dis"},{"issue":"4","key":"1624_CR22","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/jcp.30023","volume":"236","author":"L Xue","year":"2021","unstructured":"Xue L, et al. m(6) A transferase METTL3-induced lncRNA ABHD11-AS1 promotes the Warburg effect of non-small-cell lung cancer. J Cell Physiol. 2021;236(4):2649\u201358.","journal-title":"J Cell Physiol"},{"issue":"7","key":"1624_CR23","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00277-023-05283-6","volume":"102","author":"X Huang","year":"2023","unstructured":"Huang X, et al. m6A methyltransferase METTL3 facilitates multiple myeloma cell growth through the m6A modification of BZW2. Ann Hematol. 2023;102(7):1801\u201310.","journal-title":"Ann Hematol"},{"issue":"11","key":"1624_CR24","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1007\/s11010-023-04906-w","volume":"479","author":"J Bao","year":"2024","unstructured":"Bao J, et al. N6-methyladenosine-induced miR-182-5p promotes multiple myeloma tumorigenesis by regulating CAMK2N1. Mol Cell Biochem. 2024;479(11):3077\u201389.","journal-title":"Mol Cell Biochem"},{"key":"1624_CR25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.canlet.2020.04.003","volume":"483","author":"S Yao","year":"2020","unstructured":"Yao S, et al. DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo. Cancer Lett. 2020;483:87\u201397.","journal-title":"Cancer Lett"},{"issue":"1","key":"1624_CR26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13046-016-0436-6","volume":"35","author":"SH Wang","year":"2016","unstructured":"Wang SH, et al. Long non-coding RNA H19 regulates FOXM1 expression by competitively binding endogenous miR-342-3p in gallbladder cancer. J Exp Clin Cancer Res. 2016;35(1):160.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1\u20132","key":"1624_CR27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","volume":"28","author":"D Kaloni","year":"2023","unstructured":"Kaloni D, et al. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis. 2023;28(1\u20132):20\u201338.","journal-title":"Apoptosis"},{"issue":"1","key":"1624_CR28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12935-023-02955-1","volume":"23","author":"N Zhang","year":"2023","unstructured":"Zhang N, et al. Novel insights into mutual regulation between N(6)-methyladenosine modification and LncRNAs in tumors. Cancer Cell Int. 2023;23(1):127.","journal-title":"Cancer Cell Int"},{"issue":"11","key":"1624_CR29","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/biom12111647","volume":"12","author":"K Ding","year":"2022","unstructured":"Ding K, et al. Synergistically anti-multiple myeloma effects: flavonoid, non-flavonoid polyphenols, and bortezomib. Biomolecules. 2022;12(11):1647.","journal-title":"Biomolecules"},{"issue":"2","key":"1624_CR30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41419-018-1219-0","volume":"10","author":"Y Pan","year":"2019","unstructured":"Pan Y, et al. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p. Cell Death Dis. 2019;10(2):106.","journal-title":"Cell Death Dis"},{"issue":"2","key":"1624_CR31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40262-018-0679-9","volume":"58","author":"CRC Tan","year":"2019","unstructured":"Tan CRC, et al. Clinical pharmacokinetics and pharmacodynamics of bortezomib. Clin Pharmacokinet. 2019;58(2):157\u201368.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1624_CR32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-019-0747-0","volume":"12","author":"J Wang","year":"2019","unstructured":"Wang J, et al. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. J Hematol Oncol. 2019;12(1):81.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1624_CR33","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/ph17050626","volume":"17","author":"R Zhang","year":"2024","unstructured":"Zhang R, et al. beta-Elemene reverses gefitinib resistance in NSCLC Cells by inhibiting lncRNA H19-mediated autophagy. Pharmaceuticals (Basel). 2024;17(5):626.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1624_CR34","doi-asserted-by":"crossref","first-page":"1155621","DOI":"10.3389\/fonc.2023.1155621","volume":"13","author":"M Matamala Montoya","year":"2023","unstructured":"Matamala Montoya M, et al. Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment. Front Oncol. 2023;13:1155621.","journal-title":"Front Oncol"},{"issue":"14","key":"1624_CR35","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.7150\/thno.25541","volume":"8","author":"J Ren","year":"2018","unstructured":"Ren J, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018;8(14):3932\u201348.","journal-title":"Theranostics"},{"key":"1624_CR36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.canlet.2020.11.006","volume":"500","author":"YW Shermane Lim","year":"2021","unstructured":"Shermane Lim YW, et al. The double-edged sword of H19 lncRNA: Insights into cancer therapy. Cancer Lett. 2021;500:253\u201362.","journal-title":"Cancer Lett"},{"issue":"1","key":"1624_CR37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-021-02209-w","volume":"41","author":"Z Wang","year":"2022","unstructured":"Wang Z, et al. Induction of m(6)A methylation in adipocyte exosomal LncRNAs mediates myeloma drug resistance. J Exp Clin Cancer Res. 2022;41(1):4.","journal-title":"J Exp Clin Cancer Res"},{"key":"1624_CR38","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s10565-021-09690-1","volume":"39","author":"F Che","year":"2022","unstructured":"Che F, et al. METTL3 facilitates multiple myeloma tumorigenesis by enhancing YY1 stability and pri-microRNA-27 maturation in m(6)A-dependent manner. Cell Biol Toxicol. 2022;39:2033\u201350.","journal-title":"Cell Biol Toxicol"},{"key":"1624_CR39","doi-asserted-by":"crossref","first-page":"1383232","DOI":"10.3389\/fcell.2024.1383232","volume":"12","author":"S Jiang","year":"2024","unstructured":"Jiang S, et al. N6-methyladenosine-modified circ_0000337 sustains bortezomib resistance in multiple myeloma by regulating DNA repair. Front Cell Dev Biol. 2024;12:1383232.","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"1624_CR40","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.molcel.2022.02.033","volume":"82","author":"J Xiong","year":"2022","unstructured":"Xiong J, et al. Lactylation-driven METTL3-mediated RNA m(6)A modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol Cell. 2022;82(9):1660-1677 e10.","journal-title":"Mol Cell"},{"issue":"45","key":"1624_CR41","doi-asserted-by":"crossref","first-page":"6906","DOI":"10.1038\/s41388-020-01475-w","volume":"39","author":"Z Sun","year":"2020","unstructured":"Sun Z, et al. Aberrant NSUN2-mediated m(5)C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma. Oncogene. 2020;39(45):6906\u201319.","journal-title":"Oncogene"},{"issue":"5","key":"1624_CR42","first-page":"2814","volume":"40","author":"J Wang","year":"2018","unstructured":"Wang J, et al. Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184\/c-Myc axis. Oncol Rep. 2018;40(5):2814\u201325.","journal-title":"Oncol Rep"},{"issue":"11","key":"1624_CR43","volume":"51","author":"Y Yu","year":"2021","unstructured":"Yu Y, et al. Circ_0021087 acts as a miR-184 sponge and represses gastric cancer progression by adsorbing miR-184 and elevating FOSB expression. Eur J Clin Investig. 2021;51(11): e13605.","journal-title":"Eur J Clin Investig"},{"key":"1624_CR44","volume":"217","author":"W Hou","year":"2021","unstructured":"Hou W, Zhang Y. Circ_0025033 promotes the progression of ovarian cancer by activating the expression of LSM4 via targeting miR-184. Pathol Res Pract. 2021;217: 153275.","journal-title":"Pathol Res Pract"},{"key":"1624_CR45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bbrc.2021.04.108","volume":"561","author":"J Wang","year":"2021","unstructured":"Wang J. Tripterine and miR-184 show synergy to suppress breast cancer progression. Biochem Biophys Res Commun. 2021;561:19\u201325.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1624_CR46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.molcel.2015.05.003","volume":"59","author":"JX Wang","year":"2015","unstructured":"Wang JX, et al. Oxidative modification of miR-184 enables it to target Bcl-xL and Bcl-w. Mol Cell. 2015;59(1):50\u201361.","journal-title":"Mol Cell"},{"issue":"1","key":"1624_CR47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","volume":"65","author":"RS Blanc","year":"2017","unstructured":"Blanc RS, Richard S. Arginine methylation: the coming of age. Mol Cell. 2017;65(1):8\u201324.","journal-title":"Mol Cell"},{"issue":"3","key":"1624_CR48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/embo-reports\/kvf052","volume":"3","author":"J Lee","year":"2002","unstructured":"Lee J, Bedford MT. PABP1 identified as an arginine methyltransferase substrate using high-density protein arrays. EMBO Rep. 2002;3(3):268\u201373.","journal-title":"EMBO Rep"},{"key":"1624_CR49","doi-asserted-by":"crossref","first-page":"105124","DOI":"10.1016\/j.jbc.2023.105124","volume":"299","author":"M Santos","year":"2023","unstructured":"Santos M, Hwang JW, Bedford MT. CARM1 arginine methyltransferase as a therapeutic target for cancer. J Biol Chem. 2023;299:105124.","journal-title":"J Biol Chem"},{"issue":"4","key":"1624_CR50","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell. 2017;168(4):629\u201343.","journal-title":"Cell"},{"issue":"5","key":"1624_CR51","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/cancers11050634","volume":"11","author":"FH Hamdan","year":"2019","unstructured":"Hamdan FH, Johnsen SA. Perturbing enhancer activity in cancer therapy. Cancers (Basel). 2019;11(5):634.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1624_CR52","doi-asserted-by":"crossref","first-page":"17993","DOI":"10.1038\/s41598-017-18446-z","volume":"7","author":"AE Drew","year":"2017","unstructured":"Drew AE, et al. Identification of a CARM1 inhibitor with potent in vitro and in vivo activity in preclinical models of multiple myeloma. Sci Rep. 2017;7(1):17993.","journal-title":"Sci Rep"},{"issue":"26","key":"1624_CR53","doi-asserted-by":"crossref","first-page":"18480","DOI":"10.18632\/oncotarget.24883","volume":"9","author":"K Nakayama","year":"2018","unstructured":"Nakayama K, et al. TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma. Oncotarget. 2018;9(26):18480\u201393.","journal-title":"Oncotarget"},{"issue":"9","key":"1624_CR54","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1007\/s11033-023-08645-5","volume":"50","author":"L Yang","year":"2023","unstructured":"Yang L, et al. Inhibition of CARM1 suppresses proliferation of multiple myeloma cells through activation of p53 signaling pathway. Mol Biol Rep. 2023;50(9):7457\u201369.","journal-title":"Mol Biol Rep"},{"issue":"17","key":"1624_CR55","doi-asserted-by":"crossref","first-page":"13366","DOI":"10.18632\/oncotarget.24351","volume":"9","author":"L Rao","year":"2018","unstructured":"Rao L, et al. Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin((R)) protein MP0250: a preclinical study. Oncotarget. 2018;9(17):13366\u201381.","journal-title":"Oncotarget"},{"issue":"10","key":"1624_CR56","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/procel\/pwae010","volume":"15","author":"D Feng","year":"2024","unstructured":"Feng D, et al. CARM1 drives triple-negative breast cancer progression by coordinating with HIF1A. Protein Cell. 2024;15(10):744\u201365.","journal-title":"Protein Cell"},{"issue":"11","key":"1624_CR57","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1158\/0008-5472.CAN-10-0040","volume":"70","author":"D Zhao","year":"2010","unstructured":"Zhao D, et al. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res. 2010;70(11):4728\u201338.","journal-title":"Cancer Res"},{"issue":"5","key":"1624_CR58","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s12032-014-0914-7","volume":"31","author":"EB Zhang","year":"2014","unstructured":"Zhang EB, et al. c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. Med Oncol. 2014;31(5):914.","journal-title":"Med Oncol"},{"issue":"6","key":"1624_CR59","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","volume":"32","author":"KK Jovanovic","year":"2018","unstructured":"Jovanovic KK, et al. Targeting MYC in multiple myeloma. Leukemia. 2018;32(6):1295\u2013306.","journal-title":"Leukemia"},{"key":"1624_CR60","doi-asserted-by":"crossref","first-page":"1162607","DOI":"10.3389\/fimmu.2023.1162607","volume":"14","author":"L Chen","year":"2023","unstructured":"Chen L, et al. N6-methyladenosine reader YTHDF family in biological processes: structures, roles, and mechanisms. Front Immunol. 2023;14:1162607.","journal-title":"Front Immunol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01624-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01624-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01624-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:45:15Z","timestamp":1764917115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01624-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1624"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01624-z","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"102"}}